Suzhou Novoprotein Scientific Co. Ltd. A (688137) Fair Value & Analysis
Healthcare · CN · Market cap 3.8B CNY
Strengths
Risks
Fair value as of: Aug 13, 2026
From 3 valuation models · updated 12 days ago
Share price +145.6% over the past month.
Below-average quality, and trading another 236% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥31.07). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥16.41 to ¥31.07) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
47‑month range ¥28.94 – ¥114.96 · fair‑value band ¥16.41 – ¥31.07 · the ¥83.52 price screens above the ¥24.86 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Suzhou Novoprotein Scientific Co. Ltd. A (688137) currently trades at ¥83.52, while our model-based Fair Value estimate is ¥24.86, implying the stock looks roughly 70.2% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Suzhou Novoprotein Scientific Co. Ltd. A generated revenue of 150M CNY at a net margin of -51.0%. Revenue grew 11.4% year over year. It earns a return on equity of -3.7%. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥16.41 (bear case) to ¥31.07 (bull case); at ¥83.52, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 140% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -60% fair-value upside, at -70%, 688137 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (¥19.50) versus Dividend Discount (¥4.80). Highest evidence: Gordon GGM (70).
Notify me when 688137 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania.
Full company description
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, enzymes and reagents, biosimilar reference antibodies, gene and cell therapy, molecular research and diagnosis, and virus-related products, including antigens, antibodies and test kits. The company also provides protein expression and purification; industrial strain and process development; antibody development and production service; antibody screening and optimization services; and IVT mRNA/circRNA /SaRNA production services. It offers its products and services in the fields of biopharmaceuticals, mRNA vaccines and drugs, in vitro diagnostics, biological drugs, basic research of life sciences, and other areas. The company was founded in 2009 and is headquartered in Suzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Suzhou Novoprotein Scientific Co. Ltd. A reported revenue of ¥146M in FY2025 versus ¥342M in FY2021, a compound −19.1%/yr. Reported net income was −¥77.8M in FY2025.
688137 screens 70% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 634 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| argenx SE ARGX | €877.60 | €292.84 | -67% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | -77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | -60% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | -69% |
| Moderna, Inc MRNA | $63.67 | $12.77 | -80% |
| BioNTech SE 22UA | €80.60 | €52.92 | -34% |
Compare Suzhou Novoprotein Scientific Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Suzhou Novoprotein Scientific Co. Ltd. A (688137) overvalued or undervalued?
What is the fair value of 688137?
What is the quality score of 688137?
What is the revenue of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
What is the net profit margin of 688137?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Suzhou Novoprotein Scientific Co. Ltd. A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.